Feature|Articles|August 28, 2026

Preventing Batch Loss: The Growing Role of Preventive and Predictive Maintenance

Author(s)Israel Ortiz

With biopharma batch failures averaging every 40 weeks, predictive maintenance and connected monitoring are becoming critical quality levers.

Pharmaceutical manufacturers operate under some of the strictest quality requirements in any industry. Even small deviations in a facility’s environmental conditions can compromise product stability and risk batch losses that can cost manufacturers millions of dollars in lost product, investigations, and production delays. Despite improvements in manufacturing technology, batch failures still occur due to contamination, operator error, and equipment failure. On average, biopharmaceutical manufacturers experience a failure every 40 weeks.

Related to this article

How QMM Can Help the C-Suite See a  $100 Million Problem Early
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.